Fig 1 - by Nida Mansoora (11648641)

Subjects:

Effect of different treatments on ionic contents like sodium, calcium, potassium, phosphorous and soluble proteins constituents of two wheat genotypes (Markaz 19 and Ujala 16) afte... by Nida Mansoora (11648641)

Subjects:

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Treatment of Balb/c mice with P28GST after TNBS induction of colitis decreases intestinal inflammation. by Aurore Sarazin (6162698)

ETHE1-p.Arg163Gln and p.Arg163Trp are folded but have decreased stability. by Bárbara J. Henriques (627180)

Silencing of Rap1A decreases ERK and p38 activation. by Yougen Wu (830191)

Decreased miR-29b/c in GC tissue samples. by He Cui (229445)

Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo Efficacy by Maude Giroud (2017114)

“…When tested in vivo, compound <b>7</b> showed efficacy after oral dosing in a mouse model of peripheral nerve injury by decreasing plasma neurofilament light (NfL) levels at 50 mg/kg compared with vehicle-treated control mice, holding promise for the treatment of neurodegenerative and neurological disorders.…”

A picture of the 50 L small-scale environmental chamber. by Eloise Parry-Nweye (7548998)

Estimated time (in days) required for a decrease of the viral titer by 1 log₁₀ TCID₅₀/mL. by Camille Lebarbenchon (122050)

“…<p>Estimated time (in days) required for a decrease of the viral titer by 1 log₁₀ TCID₅₀/mL.…”

OP50 <i>E. coli</i>-fed nematodes are generally healthy while pathogen-fed worms demonstrate a decrease in overall health. by Michelle R. Bond (669241)

“…(B) The average pumping rate for nematodes fed <i>P. aeruginosa</i> is decreased when compared to N2 animals fed OP50. Worms with a <i>pmk-1(km25)</i> background exhibit the largest decrease in pumping rate. …”

OPC survival, proliferation, and differentiation decrease in acidic extracellular pH (PDL surface, 50 µg/ml). by Anna Jagielska (464874)

Effects of anti-TNF-α treatment on insulin sensitivity in skeletal muscle after FTox-G50 injection. by Aouatef Ait-Lounis (151054)

“…<p>Four-week-old mice were injected with etanercept (anti-TNFα, 1 mg/kg/injection) and one hour before FTox-G50-injection. …”